Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Bajorin

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|January 6, 1993
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapyD F Bajorin, R J Motzer, E Rodriguez, et al.
Investigational New Drugs|February 1, 1991
Phase II trial of cisplatin and etoposide in patients with metastatic melanomaO Eton, D F Bajorin, P B Chapman, et al.
Investigational New Drugs|January 1, 1995
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumorsH S Puc, D F Bajorin, G J Bosl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumorsR J Motzer, M Mazumdar, D F Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicityR J Motzer, M Mazumdar, G J Bosl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Recommendations for a Global Core Curriculum in Medical OncologyH H Hansen, D F Bajorin, H B Muss, et al.
Cancer Research|November 1, 1986
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic salineD F Bajorin, G J Bosl, N W Alcock, et al.
The Journal of Urology|February 26, 1999
Can p53 help select patients with invasive bladder cancer for bladder preservation?H W Herr, D F Bajorin, H I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapyM Mazumdar, D F Bajorin, J Bacik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survivalJ A McCaffrey, M Mazumdar, D F Bajorin, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|January 6, 1993
Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapyD F Bajorin, R J Motzer, E Rodriguez, et al.
Investigational New Drugs|February 1, 1991
Phase II trial of cisplatin and etoposide in patients with metastatic melanomaO Eton, D F Bajorin, P B Chapman, et al.
Investigational New Drugs|January 1, 1995
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumorsH S Puc, D F Bajorin, G J Bosl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumorsR J Motzer, M Mazumdar, D F Bajorin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicityR J Motzer, M Mazumdar, G J Bosl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Recommendations for a Global Core Curriculum in Medical OncologyH H Hansen, D F Bajorin, H B Muss, et al.
Cancer Research|November 1, 1986
Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic salineD F Bajorin, G J Bosl, N W Alcock, et al.
The Journal of Urology|February 26, 1999
Can p53 help select patients with invasive bladder cancer for bladder preservation?H W Herr, D F Bajorin, H I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapyM Mazumdar, D F Bajorin, J Bacik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survivalJ A McCaffrey, M Mazumdar, D F Bajorin, et al.
Pageof 10